NVCRNovoCure GmbHSigning up patients
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
Metastatic Non-small Cell Lung Cancer
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.7
8 insiders sold shares within a month
Since Jun 4, 2026 · was worth 10, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 734 (planned)
- Started
- Jul 31, 2024
- Main results expected
- Oct 2028
- Fully finished
- Oct 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Survival (OS)
Measured over: up to 6 years
Progression Free Survival (PFS)
Measured over: up to 6 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 1.7, since 2026-06-04, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06216301 · record last updated 2026-10-06 · checked 2026-11-09 15:47 UTC